Reversion of AHRR demethylation is a quantitative biomarker of smoking cessation

Frontiers in Psychiatry

Volumn 7, Issue APR, 2016, Pages

  Philibert, Robert ^a,b   Hollenbeck, Nancy ^a   Andersen, Eleanor ^b   McElroy, Shyheme ^a   Wilson, Scott ^a   Vercande, Kyra ^a   Beach, Steven R H ^c   Osborn, Terry ^b   Gerrard, Meg ^d   Gibbons, Frederick X ^d   Wang, Kai ^e  

^a UNIVERSITY OF IOWA   (United States)

^b University of Georgia ^*  (United States)

^c University of Georgia   (United States)

^d UNIVERSITY OF CONNECTICUT   (United States)

^e UNIVERSITY OF IOWA   (United States)

Author keywords

Aryl hydrocarbon receptor repressor; Cg05575921; Diagnostics; DNA methylation; Epigenetics; Smoking cessation

Indexed keywords

ARYL HYDROCARBON RECEPTOR REPRESSOR; BIOLOGICAL MARKER; COTININE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; DNA METHYLATION; EXHALED CARBON MONOXIDE; EXPIRED AIR; FEMALE; HUMAN; MALE; SELF REPORT; SMOKING CESSATION; SMOKING CESSATION PROGRAM;

EID: 84975318238     PISSN: None     EISSN: 16640640     Source Type: Journal    
DOI: 10.3389/fpsyt.2016.00055     Document Type: Article

References (37)

1. Centers for Disease Control and Prevention. Smoking-attributable mortality, years of potential life lost, and productivity losses-United States, 2000-2004. MMWR Morb Mortal Wkly Rep (2008) 57:1226-8.
2. Centers for Disease Control and Prevention. Vital signs: current cigarette smoking among adults aged =18 years-United States, 2005-2010. MMWR Morb Mortal Wkly Rep (2011) 60:1207-12.
3. Cahill K, Stevens S, Lancaster T. Pharmacological treatments for smoking cessation. JAMA (2014) 311:193-4. doi: 10.1001/jama.2013.283787
4. Chang P-H, Chiang C-H, Ho W-C, Wu P-Z, Tsai J-S, Guo F-R. Combination therapy of varenicline with nicotine replacement therapy is better than varenicline alone: a systematic review and meta-analysis of randomized controlled trials. BMC Public Health (2015) 15:689. doi:10.1186/s12889-015-2055-0
5. Fiore M, Jaen CR, Baker T, Bailey W, Benowitz N, Curry S, et al. Treating Tobacco Use and Dependence: 2008 Update. (2008). Available from: http://bphc.hrsa.gov/buckets/treatingtobacco.pdf
6. Jatlow P, Toll BA, Leary V, Krishnan-Sarin S, O'malley SS. Comparison of expired carbon monoxide and plasma cotinine as markers of cigarette abstinence. Drug Alcohol Depend (2008) 98:203-9. doi:10.1016/j.drugalcdep.2008.05.013
7. Hilberink SR, Jacobs JE, Van Opstal S, Van Der Weijden T, Keegstra J, Kempers PL, et al. Validation of smoking cessation self-reported by patients with chronic obstructive pulmonary disease. Int J Gen Med (2011) 4:85. doi:10.2147/IJGM.S15231
8. Cox LS, Nollen NL, Mayo MS, Choi WS, Faseru B, Benowitz NL, et al. Bupropion for smoking cessation in African American light smokers: a randomized controlled trial. J Natl Cancer Inst (2012) 104:290-8. doi:10.1093/jnci/djr513
9. Sato S, Nishimura K, Koyama H, Tsukino M, Oga T, Hajiro T, et al. Optimal cutoff level of breath carbon monoxide for assessing smoking status in patients with asthma and COPD. Chest (2003) 124:1749-54. doi:10.1378/chest.124.5.1749
10. Chatkin G, Chatkin JM, Aued G, Petersen GO, Jeremias ET, Thiesen FV. Evaluation of the exhaled carbon monoxide levels in smokers with COPD. J Bras Pneumol (2010) 36:332-8. doi:10.1590/S1806-37132010000300011
11. Florescu A, Ferrence R, Einarson T, Selby P, Soldin O, Koren G. Methods for quantification of exposure to cigarette smoking and environmental tobacco smoke: focus on developmental toxicology. Ther Drug Monit (2009) 31:14-30. doi:10.1097/FTD.0b013e3181957a3b
12. Hajek P, Mcrobbie H, Gillison F. Dependence potential of nicotine replacement treatments: effects of product type, patient characteristics, and cost to user. Prev Med (2007) 44:230-4. doi:10.1016/j.ypmed.2006.10.005
13. International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care (2009) 32:1327-34. doi:10.2337/dc09-9033
14. Dezii CM. Medication noncompliance: what is the problem? Manag Care (2000) 9:7-12.
15. Philibert R, Hollenbeck N, Andersen E, Osborn T, Gerrard M, Gibbons R, et al. A quantitative epigenetic approach for the assessment of cigarette consumption. Front Psychol (2015) 6:656. doi:10.3389/fpsyg.2015.00656
16. Andersen AM, Dogan MV, Beach SRH, Philibert RA. Current and future prospects for epigenetic biomarkers of substance use. Genes (2015) 6(4):991-1022. doi:10.3390/genes6040991
17. Zeilinger S, Kühnel B, Klopp N, Baurecht H, Kleinschmidt A, Gieger C, et al. Tobacco smoking leads to extensive genome-wide changes in DNA methylation. PLoS One (2013) 8:e63812. doi:10.1371/journal.pone.0063812
18. Tsaprouni LG, Yang T-P, Bell J, Dick KJ, Kanoni S, Nisbet J, et al. Cigarette smoking reduces DNA methylation levels at multiple genomic loci but the effect is partially reversible upon cessation. Epigenetics (2014) 9:1382-96. doi:10.4161/15592294.2014.969637
19. Philibert R, Penaluna B, White T, Shires S, Gunter TD, Liesveld J, et al. A pilot examination of the genome-wide DNA methylation signatures of subjects entering and exiting short-term alcohol dependence treatment programs. Epigenetics (2014) 9:1-7. doi:10.4161/epi.32252
20. Shiffman S, Hufford M, Hickcox M, Paty JA, Gnys M, Kassel JD. Remember that? A comparison of real-time versus retrospective recall of smoking lapses. J Consult Clin Psychol (1997) 65:292-300. doi:10.1037/0022-006X.65.2.292.a
21. Besingi W, Johansson Å. Smoke related DNA methylation changes in the etiology of human disease. Hum Mol Genet (2013) 23:2290-7. doi:10.1093/hmg/ddt62
22. Bucholz KK, Cadoret R, Cloninger CR, Dinwiddie SH, Hesselbrock VM, Nurnberger JI Jr, et al. A new, semi-structured psychiatric interview for use in genetic linkage studies: a report on the reliability of the SSAGA. J Stud Alcohol (1994) 55:149-58. doi:10.15288/jsa.1994.55.149
23. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The Fagerstrom test for nicotine dependence: a revision of the Fagerstrom tolerance questionnaire. Br J Addict (1991) 86:1119-27. doi:10.1111/j.1360-0443.1991.tb01879.x
24. Lahiri DK, Schnabel B. DNA isolation by a rapid method from human blood samples: effects of MgCl2, EDTA, storage time, and temperature on DNA yield and quality. Biochem Genet (1993) 31:321-8. doi:10.1007/BF00553174
25. Dogan MV, Shields B, Cutrona C, Gao L, Gibbons FX, Simons R, et al. The effect of smoking on DNA methylation of peripheral blood mononuclear cells from African American women. BMC Genomics (2014) 15:151. doi:10.1186/1471-2164-15-151
26. Philibert RA, Zadorozhnyaya O, Beach SR, Brody GH. Comparison of the genotyping results using DNA obtained from blood and saliva. Psychiatr Genet (2008) 18:275-81. doi:10.1097/YPG.0b013e3283060f81
27. Cohen B, Mcginnis S, Salsberg E. Physician Behavior and Practice Patterns Related to Smoking Cessation. Washington, DC: Association of American Medical Colleges (2007).
28. Philibert RA, Beach SR, Brody GH. Demethylation of the aryl hydrocarbon receptor repressor as a biomarker for nascent smokers. Epigenetics (2012) 7:1331-8. doi:10.4161/epi.22520
29. Teschendorff AE, Yang Z, Wong A, Pipinikas CP, Jiao Y, Jones A, et al. Correlation of smoking-associated dna methylation changes in buccal cells with dna methylation changes in epithelial cancer. JAMA Oncol (2015) 1(4):476-85. doi:10.1001/jamaoncol.2015.1053
30. Roese NJ, Jamieson DW. Twenty years of bogus pipeline research: a critical review and meta-analysis. Psychol Bull (1993) 114:363-75. doi:10.1037/0033-2909.114.2.363
31. Volpp KG, Galvin R. Reward-based incentives for smoking cessation: how a carrot became a stick. JAMA (2014) 311:909-10. doi:10.1001/jama.2014.418
32. Halpern SD, French B, Small DS, Saulsgiver K, Harhay MO, Audrain-Mcgovern J, et al. Randomized trial of four financial-incentive programs for smoking cessation. N Engl J Med (2015) 372:2108-17. doi:10.1056/NEJMoa1414293
33. Hetherington J, Coutts R, Davison K. An evaluation of a novel biomarker feedback intervention on smoking cessation: a pilot study. J Smok Cessat (2012) 7:80-8. doi:10.1017/jsc.2012.16
34. Zhang Y, Yang R, Burwinkel B, Breitling LP, Holleczek B, Schöttker B, et al. F2RL3 methylation in blood DNA is a strong predictor of mortality. Int J Epidemiol (2014) 43(4):1215-25. doi:10.1093/ije/dyu006
35. Zhang Y, Schöttker B, Florath I, Stock C, Butterbach K, Holleczek B, et al. Smoking-associated DNA methylation biomarkers and their predictive value for all-cause and cardiovascular mortality. Environ Health Perspect (2016) 124(1):67-74. doi:10.1289/ehp.1409020
36. Toperoff G, Aran D, Kark JD, Rosenberg M, Dubnikov T, Nissan B, et al. Genome-wide survey reveals predisposing diabetes type 2-related DNA methylation variations in human peripheral blood. Hum Mol Genet (2012) 21:371-83. doi:10.1093/hmg/ddr472
37. Almén MS, Nilsson EK, Jacobsson JA, Kalnina I, Klovins J, Fredriksson R, et al. Genome-wide analysis reveals DNA methylation markers that vary with both age and obesity. Gene (2014) 548:61-7. doi:10.1016/j.gene.2014.07.009